A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjogren's Syndrome

Trial Profile

A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjogren's Syndrome

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs BMS 986142 (Primary) ; Lulizumab pegol (Primary)
  • Indications Sjogren's syndrome
  • Focus Proof of concept; Therapeutic Use
  • Acronyms POC H2H study
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 01 Aug 2017 This study has been completed in Greece (End date:2017-07-24).
    • 26 Jul 2017 Planned number of patients changed from 160 to 80.
    • 14 Jun 2017 Status changed from recruiting to discontinued due to inability to meet protocol objectives
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top